People with HIV are at increased risk for heart failure
The Kaiser Permanente study found the risk difference was more pronounced in women, Asians and Pacific Islanders, and people under 40.
Kaiser Permanente
Division of Research Spotlight
The Kaiser Permanente Division of Research conducts, publishes, and disseminates epidemiologic and health services research to improve the health and medical care of Kaiser Permanente members and society at large. We seek to understand the determinants of illness and well-being, and to improve the quality and cost-effectiveness of health care. Currently, DOR’s 550-plus staff is working on more than 350 epidemiological and health services research projects.
Higher risk of dementia for older adults living with HIV
A study reviewing 16 years of patient data found nearly double the rate of dementia among people with HIV compared with those without HIV. The rate of dementia decreased over time for both groups but remained higher for those with HIV, reported research published in the journal AIDS.
No serious health effects linked to mRNA COVID-19 vaccines
Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 vaccines.
HIV prevention treatment shows gaps among key populations
A large, detailed look by Kaiser Permanente researchers at patients taking HIV-prevention drug therapy finds strong adherence soon after patients get the prescription, but less consistent use thereafter, particularly among groups considered high priority for receiving the medication.
5 Questions for . . . Ousseny Zerbo
Division of Research investigator Ousseny Zerbo, PhD, describes his long journey from his childhood and education in Burkina Faso to becoming an epidemiologist in Northern California.
New tool for early identification of COVID-19 surges
Health systems could use data from routine clinical care to identify the onset of upcoming COVID-19 surges as many as 6 weeks before they occur, Kaiser Permanente researchers found in a study published in the journal BMJ Open.
COVID-19 vaccine trial enrolls children aged 5-11 at 3 sites in Northern California
About 75 children are scheduled to receive their first vaccination against COVID-19 as part of the Pfizer/BioNTech vaccine clinical trial through Kaiser Permanente Northern California.
Kaiser Permanente data key to nation’s COVID-19 vaccine surveillance strategy
Kaiser Permanente’s Vaccine Study Center is leading a key part of the national safety surveillance effort for the COVID-19 vaccines, tracking patient data for serious side effects.
Kaiser Permanente Northern California deepens its COVID-19 research agenda
Researchers and clinicians with Kaiser Permanente Northern California are developing a wide-ranging research agenda to beat COVID-19, working at the accelerated pace demanded by a worldwide pandemic.
It’s flu season: What you need to know about the research
What does it take to be sure the annual flu vaccine is effective and safe? Research. In a podcast, Nicola Klein, head of the Vaccine Study Center, tackles some common questions about the vaccine and recent findings.
